Skip to main content

Table 2 Multivariate analysis for Overall Survival for selected prognostic factors in NSCLC. A model was built for each variable of interest. All the variables listed at the upper file were included in the multivariabte Cox model, but the hazard ratios are shown only for those covariates that remained statistically significant during the forward stepwise analysis

From: Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Model 1
Covariates Age, Histology, Smoking status, ECOG PS, platinum treatment, comorbidity, BMI, weight loss, nodal status, pre-treatment fasting plasma glucose (FPG).
Variables in the equation Parameter Level Hazard Ratio 95% Confidence Interval p-value
Pre-treatment FPG Continuous 1.134 1.066–1.207 < 0.001
Platinum treatment Carboplatin vs cisplatin 1.657 1.121–2.451 0.011
Comorbidity Yes vs No 1.508 1.020–2.229 0.039
Model 2
Covariates Age, Histology, Smoking status, ECOG PS, platinum treatment, comorbidity, BMI, weight loss, nodal status, metabolic control groups.
Variables in the equation Parameter Level Hazard Ratio 95% Confidence Interval p-value
Metabolic control groups No diabetes (reference group)    
HbA1c ≤7 1.342 0.752–2.395 0.319
HbA1c 7.1–8.5 0.830 0.400–1.719 0.616
HbA1c > 8.5 4.534 2.210–9.301 < 0.001
Platinum treatment Carboplatin vs cisplatin 1.946 1.264–2.996 0.002
Comorbidity Yes vs No 1.720 1.125–2.632 0.012
Model 3
Covariates Age, Histology, Smoking status, ECOG PS, platinum treatment, comorbidity, BMI, weight loss, nodal status, insulin treatment.
Variables in the equation Parameter Level Hazard Ratio 95% Confidence Interval p-value
Insulin treatment Yes vs No 3.225 1.906–5.456 < 0.001
Platinum treatment Carboplatin vs cisplatin 1.574 1.075–2.306 0.020
  1. Abbreviations: BMI body mass index, ECOG PS Eastern Cooperative Oncology Group performance status, FPG fasting plasma glucose, HbA1c glycated haemoglobin